June 10, 2022
Weil is advising international insurance broking group Howden on its acquisition of TigerRisk Partners, a leading risk, capital and strategic advisor to the global insurance and reinsurance industries.
The deal further consolidates Howden’s position as a global re/insurance intermediary, creating a $30 billion gross written premium business with an enterprise value of more than $13 billion, employing 12,000 people across 45 countries and represents Howden Group’s continued investment in the U.S., following its recent acquisition of Align Financial Holdings in August 2021 on which Weil also advised. Weil also represented Howden Group on its acquisition of U.K.-based insurer Aston Lark in October 2021 and on its acquisition of Italian insurance broker Assiteca, in May 2022.
Weil’s transatlantic strength in complex and regulated M&A played an important part in concluding the transaction.
The Weil team is being led in London by Private Equity partner Jonathan Wood supported by associates Jessica Corr and Lucia Azzi and trainee Venetia Hudd, and the Weil team in New York is being led by M&A partner Raymond Gietz, supported by associates Chukwudi Udeogalanya, Jason Klig, Dorothy Coco and Chelsea Carpenter. The team also includes Executive Compensation & Benefits partner Amy Rubin and associate Nathan Gross; International Tax head Devon Bodoh and Tax associates Carlos Para and Jonathan Vita; Employment Litigation counsel Rebecca Sivitz and associate Paulina Cohen; Litigation associate Matthew Gibbon; Employment counsel Thomas Weatherill and associate Edward Dickinson; Antitrust partner Vadim Brusser, counsel Michael Naughton and Neil Rigby, and associate Lucy Peckham; Banking partner Damian Ridealgh, counsel Kevin Whittam and associate Alan Wen; Technology & IP Transactions partner Dennis Adams and associates Alex Theuer and Ruth Fisher; Privacy counsel Olivia Greer; Regulatory Transactions counsel Timothy Welch and associate Ariel Fliman; and Real Estate counsel Laura Murray.
Completion of the deal is subject to regulatory approvals and clearances.